Literature DB >> 21098124

The essential function for serum response factor in T-cell development reflects its specific coupling to extracellular signal-regulated kinase signaling.

Anastasia Mylona1, Robert Nicolas, Diane Maurice, Mathew Sargent, David Tuil, Dominique Daegelen, Richard Treisman, Patrick Costello.   

Abstract

Serum response factor (SRF) recruits members of two families of signal-regulated coactivators, the extracellular signal-regulated kinase (ERK)-regulated ternary complex factors (TCFs) and the actin-regulated myocardin-related transcription factors (MRTFs), to its target genes through its DNA-binding domain. Whether coactivator association is required for SRF function in vivo and whether particular SRF functions reflect specific coupling to one or the other signal pathway have remained largely unexplored. We show that SRF is essential for thymocyte positive selection and thymic T(reg) and NK T-cell development but dispensable for early thymocyte development and negative selection. Expression of wild-type SRF, or mutants lacking the N-terminal phosphorylation sites or C-terminal transcriptional activation domain, restores positive selection in SRF null thymocytes. In contrast, SRF.V194E, which cannot recruit TCF or MRTF family members, is inactive, although it is recruited to target genes. Fusion of a TCF C-terminal activation domain to SRF.V194E effectively restores ERK-dependent single-positive (SP) thymocyte development. The resulting SP thymocytes exhibit normal surface marker expression and proliferation following T-cell receptor cross-linking. Thus, ERK signaling through the TCF pathway to SRF is necessary and sufficient for SRF function in thymocyte positive selection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21098124      PMCID: PMC3019971          DOI: 10.1128/MCB.01058-10

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  59 in total

1.  Thymocyte development in early growth response gene 1-deficient mice.

Authors:  Matthew Bettini; Hongkang Xi; Jeffrey Milbrandt; Gilbert J Kersh
Journal:  J Immunol       Date:  2002-08-15       Impact factor: 5.422

2.  Actin dynamics control SRF activity by regulation of its coactivator MAL.

Authors:  Francesc Miralles; Guido Posern; Alexia-Ileana Zaromytidou; Richard Treisman
Journal:  Cell       Date:  2003-05-02       Impact factor: 41.582

3.  Occupation of the c-fos serum response element in vivo by a multi-protein complex is unaltered by growth factor induction.

Authors:  R E Herrera; P E Shaw; A Nordheim
Journal:  Nature       Date:  1989-07-06       Impact factor: 49.962

4.  Tolerance in T-cell-receptor transgenic mice involves deletion of nonmature CD4+8+ thymocytes.

Authors:  P Kisielow; H Blüthmann; U D Staerz; M Steinmetz; H von Boehmer
Journal:  Nature       Date:  1988-06-23       Impact factor: 49.962

5.  Ternary complex factor SAP-1 is required for Erk-mediated thymocyte positive selection.

Authors:  Patrick S Costello; Robert H Nicolas; Yasuyuki Watanabe; Ian Rosewell; Richard Treisman
Journal:  Nat Immunol       Date:  2004-02-08       Impact factor: 25.606

6.  Myocardin and ternary complex factors compete for SRF to control smooth muscle gene expression.

Authors:  Zhigao Wang; Da-Zhi Wang; Dirk Hockemeyer; John McAnally; Alfred Nordheim; Eric N Olson
Journal:  Nature       Date:  2004-03-11       Impact factor: 49.962

Review 7.  Ets ternary complex transcription factors.

Authors:  Gilles Buchwalter; Christian Gross; Bohdan Wasylyk
Journal:  Gene       Date:  2004-01-07       Impact factor: 3.688

8.  Targeted inactivation of serum response factor in the developing heart results in myocardial defects and embryonic lethality.

Authors:  Ara Parlakian; David Tuil; Ghislaine Hamard; Geneviève Tavernier; Daniele Hentzen; Jean-Paul Concordet; Denise Paulin; Zhenlin Li; Dominique Daegelen
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

9.  Serum response factor is crucial for actin cytoskeletal organization and focal adhesion assembly in embryonic stem cells.

Authors:  Gerhard Schratt; Ulrike Philippar; Jürgen Berger; Heinz Schwarz; Olaf Heidenreich; Alfred Nordheim
Journal:  J Cell Biol       Date:  2002-02-11       Impact factor: 10.539

10.  Transgenic mice with hematopoietic and lymphoid specific expression of Cre.

Authors:  Jasper de Boer; Adam Williams; George Skavdis; Nicola Harker; Mark Coles; Mauro Tolaini; Trisha Norton; Keith Williams; Kathleen Roderick; Alexandre J Potocnik; Dimitris Kioussis
Journal:  Eur J Immunol       Date:  2003-02       Impact factor: 5.532

View more
  13 in total

1.  Soluble SORLA Enhances Neurite Outgrowth and Regeneration through Activation of the EGF Receptor/ERK Signaling Axis.

Authors:  Jessica Stupack; Xiao-Peng Xiong; Lu-Lin Jiang; Tongmei Zhang; Lisa Zhou; Alex Campos; Barbara Ranscht; William Mobley; Elena B Pasquale; Huaxi Xu; Timothy Y Huang
Journal:  J Neurosci       Date:  2020-06-29       Impact factor: 6.167

2.  Opposing effects of Elk-1 multisite phosphorylation shape its response to ERK activation.

Authors:  Anastasia Mylona; Francois-Xavier Theillet; Charles Foster; Tammy M Cheng; Francesc Miralles; Paul A Bates; Philipp Selenko; Richard Treisman
Journal:  Science       Date:  2016-10-14       Impact factor: 47.728

Review 3.  Regulation of primary response genes.

Authors:  Trent Fowler; Ranjan Sen; Ananda L Roy
Journal:  Mol Cell       Date:  2011-11-04       Impact factor: 17.970

4.  Optimization of transcription factor binding map accuracy utilizing knockout-mouse models.

Authors:  Wolfgang Krebs; Susanne V Schmidt; Alon Goren; Dominic De Nardo; Larisa Labzin; Anton Bovier; Thomas Ulas; Heidi Theis; Michael Kraut; Eicke Latz; Marc Beyer; Joachim L Schultze
Journal:  Nucleic Acids Res       Date:  2014-11-05       Impact factor: 16.971

5.  Myocardin-related transcription factors are required for skeletal muscle development.

Authors:  Bercin K Cenik; Ning Liu; Beibei Chen; Svetlana Bezprozvannaya; Eric N Olson; Rhonda Bassel-Duby
Journal:  Development       Date:  2016-07-06       Impact factor: 6.868

6.  MRTF-SRF signaling is required for seeding of HSC/Ps in bone marrow during development.

Authors:  Patrick Costello; Mathew Sargent; Diane Maurice; Cyril Esnault; Katie Foster; Fernando Anjos-Afonso; Richard Treisman
Journal:  Blood       Date:  2015-01-08       Impact factor: 22.113

7.  Actin-dependent activation of serum response factor in T cells by the viral oncoprotein tip.

Authors:  Kristin Katsch; Sarah Jill de Jong; Jens-Christian Albrecht; Julia Steger; Harald Genth; Guido Posern; Brigitte Biesinger
Journal:  Cell Commun Signal       Date:  2012-03-03       Impact factor: 5.712

8.  Somatic RHOA mutation in angioimmunoblastic T cell lymphoma.

Authors:  Mamiko Sakata-Yanagimoto; Terukazu Enami; Kenichi Yoshida; Yuichi Shiraishi; Ryohei Ishii; Yasuyuki Miyake; Hideharu Muto; Naoko Tsuyama; Aiko Sato-Otsubo; Yusuke Okuno; Seiji Sakata; Yuhei Kamada; Rie Nakamoto-Matsubara; Nguyen Bich Tran; Koji Izutsu; Yusuke Sato; Yasunori Ohta; Junichi Furuta; Seiichi Shimizu; Takuya Komeno; Yuji Sato; Takayoshi Ito; Masayuki Noguchi; Emiko Noguchi; Masashi Sanada; Kenichi Chiba; Hiroko Tanaka; Kazumi Suzukawa; Toru Nanmoku; Yuichi Hasegawa; Osamu Nureki; Satoru Miyano; Naoya Nakamura; Kengo Takeuchi; Seishi Ogawa; Shigeru Chiba
Journal:  Nat Genet       Date:  2014-01-12       Impact factor: 41.307

9.  MKL1/2 and ELK4 co-regulate distinct serum response factor (SRF) transcription programs in macrophages.

Authors:  Lan Xie
Journal:  BMC Genomics       Date:  2014-04-23       Impact factor: 3.969

Review 10.  Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Giuseppe Montalto; Melchiorre Cervello; Ferdinando Nicoletti; Paolo Fagone; Grazia Malaponte; Maria C Mazzarino; Saverio Candido; Massimo Libra; Jörg Bäsecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Michele Milella; Agostino Tafuri; Lucio Cocco; Camilla Evangelisti; Francesca Chiarini; Alberto M Martelli
Journal:  Oncotarget       Date:  2012-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.